Interleukin-6 Signaling Drives Fibrosis in Unresolved Inflammation
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Fibrosis in response to tissue damage or persistent inflammation is a pathological hallmark of many chronic degenerative diseases. By using a model of acute peritoneal inflammation, we have examined how repeated inflammatory activation promotes fibrotic tissue injury. In this context, fibrosis was strictly dependent on interleukin-6 (IL-6). Repeat inflammation induced IL-6-mediated T helper 1 (Th1) cell effector commitment and the emergence of STAT1 (signal transducer and activator of transcription-1) activity within the peritoneal membrane. Fibrosis was not observed in mice lacking interferon-γ (IFN-γ), STAT1, or RAG-1. Here, IFN-γ and STAT1 signaling disrupted the turnover of extracellular matrix by metalloproteases. Whereas IL-6-deficient mice resisted fibrosis, transfer of polarized Th1 cells or inhibition of MMP activity reversed this outcome. Thus, IL-6 causes compromised tissue repair by shifting acute inflammation into a more chronic profibrotic state through induction of Th1 cell responses as a consequence of recurrent inflammation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cellular and molecular mechanisms of fibrosis
Wynn, T. (2008) · The Journal of Pathology · doi:10.1002/path.2277 · Cited by 4,495
Roberts, A. B., Sporn, M. B., Assoian, R. K., Smith, J. M., Roche, N. S., Wakefield, L. M., Heine, U. I., Liotta, L. A., Falanga, V, & Kehrl, J. H. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.12.4167 · Cited by 2,866
Grivennikov, S., Karin, E., Terzic, J., Mucida, D., Yu, G.-Y., Vallabhapurapu, S., Scheller, J., Rose-John, S., Cheroutre, H., Eckmann, L., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.001 · Cited by 2,155
Hirano, T., Yasukawa, K., Harada, H., Taga, T., Watanabe, Y., Matsuda, T., Kashiwamura, S.-I., Nakajima, K., Koyama, K., Iwamatsu, A., et al. (1986) · Nature · doi:10.1038/324073a0 · Cited by 2,139 · cited 1×
“However, they do not eliminate the involvement of IL-6-driven B cell antibody generation (Hirano et al., 1986), which in turn may drive antibody-mediated tissue injury.”
BackgroundToll Pathway-Dependent Blockade of CD4 + CD25 + T Cell-Mediated Suppression by Dendritic Cells
Pasare, C., & Medzhitov, R. (2003) · Science · doi:10.1126/science.1078231 · Cited by 1,997
Impaired immune and acute-phase responses in interleukin-6-deficient mice
Kopf, M., Baumann, H., Freer, G., Freudenberg, M., Lamers, M., Kishimoto, T., Zinkernagel, R., Bluethmann, H., & Köhler, G. (1994) · Nature · doi:10.1038/368339a0 · Cited by 1,768 · cited 5×
“IL-6deficient (Il6 / ) (Kopf et al., 1994), IL-6R-deficient (Cd126 / ) (Jones et al., 2010), Smad3 / (Zhu et al., 1998), and IFN-g-deficient (Ifng / ) mice, recombinase-activated gene-1 (Rag1 / ) on a C57BL/6 background were bred in house from breeding pairs originally purchased from The Jackson…”
BackgroundInfluentialFibrotic disease and the TH1/TH2 paradigm
Wynn, T. A. (2004) · Nature Reviews Immunology · doi:10.1038/nri1412 · Cited by 1,765
Zhu, Z., Homer, R. J., Wang, Z., Chen, Q., Geba, G. P., Wang, J., Zhang, Y., & Elias, J. A. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5909 · Cited by 1,719
Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases
Wynn, T. A. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31487 · Cited by 1,456
STAT3 Mutations in the Hyper-IgE Syndrome
Holland, S. M., DeLeo, F. R., Elloumi, H. Z., Hsu, A. P., Uzel, G., Brodsky, N., Freeman, A. F., Demidowich, A., Davis, J., Turner, M. L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073687 · Cited by 1,221
Cited by
IL-6 as a keystone cytokine in health and disease
Hunter, C. A., & Jones, S. A. (2015) · Nature Immunology · doi:10.1038/ni.3153 · Cited by 2,511
Self-citationIL-6 in inflammation, autoimmunity and cancer
Hirano, T. (2021) · International Immunology · doi:10.1093/intimm/dxaa078 · Cited by 1,453
“However, the effect of IL-6 on the diversity of T h 1 and T h 2 cells is not simple: IL-6 induced by repeated inflammation is responsible for T h 1 cell responses in peritoneal fibrosis (157).”
BackgroundRecent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer
Jones, S. A., & Jenkins, B. J. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0066-7 · Cited by 1,102
Self-citationMack, M. (2018) · Matrix Biology · doi:10.1016/j.matbio.2017.11.010 · Cited by 514
The role of IL-6 in host defence against infections: immunobiology and clinical implications
Rose-John, S., Winthrop, K., & Calabrese, L. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.83 · Cited by 424
T Cells in Fibrosis and Fibrotic Diseases
Zhang, M., & Zhang, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01142 · Cited by 330
Fibrosis—a lethal component of systemic sclerosis
Ho, Y. Y., Lagares, D., Tager, A. M., & Kapoor, M. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2014.53 · Cited by 306
IL-6 signalling pathways and the development of type 2 diabetes
Akbari, M., & Hassan-Zadeh, V. (2018) · Inflammopharmacology · doi:10.1007/s10787-018-0458-0 · Cited by 302
Pathological mechanisms and therapeutic outlooks for arthrofibrosis
Usher, K. M., Zhu, S., Mavropalias, G., Carrino, J. A., Zhao, J., & Xu, J. (2019) · Bone Research · doi:10.1038/s41413-019-0047-x · Cited by 285
Contribution of metabolic reprogramming to macrophage plasticity and function
EL Kasmi, K. C., & Stenmark, K. R. (2015) · Seminars in Immunology · doi:10.1016/j.smim.2015.09.001 · Cited by 277
Vascular niche IL-6 induces alternative macrophage activation in glioblastoma through HIF-2α
Wang, Q., He, Z., Huang, M., Liu, T., Wang, Y., Xu, H., Duan, H., Ma, P., Zhang, L., Zamvil, S. S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03050-0 · Cited by 277
Two-Step Senescence-Focused Cancer Therapies
Sieben, C. J., Sturmlechner, I., van de Sluis, B., & van Deursen, J. M. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.04.006 · Cited by 222
Barrow, F., Khan, S., Fredrickson, G., Wang, H., Dietsche, K., Parthiban, P., Robert, S., Kaiser, T., Winer, S., Herman, A., et al. (2021) · Hepatology · doi:10.1002/hep.31755 · Cited by 210
Zhu, Y., Soderblom, C., Krishnan, V., Ashbaugh, J., Bethea, J. R., & Lee, J. K. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.10.024 · Cited by 199
Bhaumik, S., & Basu, R. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00254 · Cited by 119
Hu, L., Yu, Y., Huang, H., Fan, H., Hu, L., Yin, C., Li, K., Fulton, D. J. R., & Chen, F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00696 · Cited by 100
Repetitive intradermal bleomycin injections evoke T-helper cell 2 cytokine-driven pulmonary fibrosis
Singh, B., Kasam, R. K., Sontake, V., Wynn, T. A., & Madala, S. K. (2017) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00184.2017 · Cited by 48
Zhu, H., Liu, X., Ding, Y., Tan, K., Ni, W., Ouyang, W., Tang, J., Ding, X., Zhao, J., Hao, Y., et al. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02675-1 · Cited by 19
Astrab, L. R., Skelton, M. L., & Caliari, S. R. (2024) · doi:10.1101/2024.10.13.618034 · Cited by 2
Metadata
- Authors
- Fielding, C. A., Jones, G. W., McLoughlin, R. M., McLeod, L., Hammond, V. J., Uceda, J., Williams, A. S., Lambie, M., Foster, T. L., Liao, C.-T., Rice, C. M., Greenhill, C. J., Colmont, C. S., Hams, E., Coles, B., Kift-Morgan, A., Newton, Z., Craig, K. J., Williams, J. D., Williams, G. T., Davies, S. J., Humphreys, I. R., O’Donnell, V. B., Taylor, P. R., Jenkins, B. J., Topley, N., & Jones, S. A.
- Venue
- Immunity
- Publisher
- Elsevier BV
- Published
- 2014-01
- Volume
- 40
- Issue
- 1
- Pages
- 40-50
- ISSN
- 1074-7613 (ISSN-L)
- OpenAlex
- W1976363248
- Cited by
- 371
- References
- 59
- FWCI
- 14.79
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.